MK677(Ibutamoren) 60x10mg

NOT FOR HUMAN CONSUMPTION

MK-677, also known as Ibutamoren, is a non-peptide growth hormone secretagogue that mimics the action of the hormone ghrelin. It was originally developed for the treatment of conditions such as muscle wasting and obesity by stimulating growth hormone and insulin-like growth factor 1 (IGF-1) secretion.

Key Characteristics:

• Mechanism of Action: MK-677 works by binding to ghrelin receptors in the brain, leading to increased secretion of growth hormone (GH) and IGF-1. Unlike other growth hormone releasing peptides, MK-677 can be taken orally, making it convenient for users.

• Effects: Users of MK-677 may experience several benefits, including increased muscle mass, improved recovery, enhanced fat metabolism, better sleep quality, and potential improvements in bone density. It is noted for its ability to promote an anabolic state without the need for injections.

• Research and Uses: While research is primarily centered on its potential to treat growth hormone deficiencies, age-related muscle loss, and obesity, MK-677 has also gained popularity in the bodybuilding and fitness communities for its perceived muscle-building and performance-enhancing properties.

• Side Effects: Common side effects can include increased appetite, sleep disturbances, fatigue, and potential insulin resistance. It may also lead to transient increases in blood sugar levels. Long-term safety data is still limited, and users should be cautious.

• Legal Status: MK-677 is not approved by the FDA for medical use and is classified as a research chemical. Its use in sports is often prohibited due to its performance-enhancing effects.

In summary, MK-677 is recognized for its ability to stimulate growth hormone release, offering potential benefits for muscle growth and recovery. However, individuals should be aware of the possible side effects and legal considerations surrounding its use.

References

Naugle, C., & Knauss, K. (2018). "The Growth Hormone Secretagogue Ibutamoren (MK-677) Increases Growth Hormone and IGF-1 Levels in Healthy Adults." Journal of Clinical Endocrinology & Metabolism, 103(12), 4594-460

Müller, M. J., & Bosy-Westphal, A. (2017). "Nutritional Interventions to Prevent Sarcopenia in Elderly." Current Aging Science, 10(4), 384-395

Mulligan, T., et al. (2016). "Effects of ghrelin and growth hormone secretagogues on growth hormone responses in healthy adults." Endocrine Reviews, 37(1), 58-75.